Biocept Akcija

Biocept EV/FCF

Delisted

Vrijednost EV/FCF (Вредност предузећа према слободном готовинском току) od Biocept (BIOC) na dan 5. авг 2026. je 0,40. Prethodne godine, EV/FCF (Вредност предузећа према слободном готовинском току) je bio -10,19 — promjena od -103,97% (viši).

EV/FCF

0,40

YoY

-103,97%

Zadnja ažuriranja:

EV/FCF (Вредност предузећа према слободном готовинском току) od Biocept je 2026 0,40 . EV/FCF (Вредност предузећа према слободном готовинском току) od Biocept je bio 2025 -10,19 . Pad je time -103,97% viši u odnosu na prethodnu godinu.
Access this data via the Eulerpool API

Biocept Анализа акција

Šta radi Biocept? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept je jedna od najpopularnijih kompanija na Eulerpool.

Često postavljena pitanja o akciji Biocept

EV/FCF (Вредност предузећа према слободном готовинском току) kompanije Biocept iznosi 0,40 u 2026. godini.

EV/FCF (Вредност предузећа према слободном готовинском току) od Biocept se promijenio sa -10,19 na 0,40, što predstavlja promjenu od -103,97%. Vrijednost je viši nego prethodne godine.

Na Eulerpool-u možete pronaći potpuni historijski razvoj EV/FCF (Вредност предузећа према слободном готовинском току) Biocept od 2006. — sa godišnjim vrijednostima, grafikonima i detaljnom analizom.

Однос EV/FCF мери вредност предузећа у односу на слободан готовински ток и обухвата праву генерисање готовине пословања.

Da biste proverili EV/FCF (Вредност предузећа према слободном готовинском току)'s, bitno je da ga uporedite sa konkurentima u istoj industriji i sektoru. Na Eulopoolu, možete pronaći direktna upoređivanja industrije za EV/FCF (Вредност предузећа према слободном готовинском току).

Dobar varira u zavisnosti od industrije i faze razvoja preduzeća. Na Eulopoolu, možete porediti EV/FCF (Вредност предузећа према слободном готовинском току)'s Biocept sa sličnim preduzećima u sektoru i prosekom industrije da biste proverili da li je atraktivan.

Access this data via the Eulerpool API

Вредновање — Biocept

Sve ključne metrike — Biocept

Раст